Back to Search Start Over

The Role of PET Imaging in Patients with Prion Disease: A Literature Review.

Authors :
Mattoli MV
Giancipoli RG
Cocciolillo F
Calcagni ML
Taralli S
Source :
Molecular imaging and biology [Mol Imaging Biol] 2024 Apr; Vol. 26 (2), pp. 195-212. Date of Electronic Publication: 2024 Feb 01.
Publication Year :
2024

Abstract

Prion diseases are rare, rapidly progressive, and fatal incurable degenerative brain disorders caused by the misfolding of a normal protein called PrPC into an abnormal protein called PrPSc. Their highly variable clinical presentation mimics various degenerative and non-degenerative brain disorders, making diagnosis a significant challenge for neurologists. Currently, definitive diagnosis relies on post-mortem examination of nervous tissue to detect the pathogenic prion protein. The current diagnostic criteria are limited. While structural magnetic resonance imaging (MRI) remains the gold standard imaging modality for Creutzfeldt-Jakob disease (CJD) diagnosis, positron emission tomography (PET) using <superscript>18</superscript> fluorine-fluorodeoxyglucose ( <superscript>18</superscript> F-FDG) and other radiotracers have demonstrated promising potential in the diagnostic assessment of prion disease. In this context, a comprehensive and updated review exclusively focused on PET imaging in prion diseases is still lacking. We review the current value of PET imaging with <superscript>18</superscript> F-FDG and non-FDG tracers in the diagnostic management of prion diseases. From the collected data, <superscript>18</superscript> F-FDG PET mainly reveals cortical and subcortical hypometabolic areas in prion disease, although fails to identify typical pattern or laterality abnormalities to differentiate between genetic and sporadic prion diseases. Although the rarity of prion diseases limits the establishment of a definitive hypometabolism pattern, this review reveals some more prevalent <superscript>18</superscript> F-FDG patterns associated with each disease subtype. Interestingly, in both sporadic and genetic prion diseases, the hippocampus does not show significant glucose metabolism alterations, appearing as a useful sign in the differential diagnosis with other neurodegenerative disease. In genetic prion disease forms, PET abnormality precedes clinical manifestation. Discordant diagnostic value for amyloid tracers among different prion disease subtypes was observed, needing further investigation. PET has emerged as a potential valuable tool in the diagnostic armamentarium for CJD. Its ability to visualize functional and metabolic brain changes provides complementary information to structural MRI, aiding in the early detection and confirmation of CJD.<br /> (© 2024. The Author(s), under exclusive licence to World Molecular Imaging Society.)

Details

Language :
English
ISSN :
1860-2002
Volume :
26
Issue :
2
Database :
MEDLINE
Journal :
Molecular imaging and biology
Publication Type :
Academic Journal
Accession number :
38302686
Full Text :
https://doi.org/10.1007/s11307-024-01895-0